---
title: "Lakewood-Amedex Biotherapeutics soars 212% on Nu-3 drug data"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293482150.md"
description: "Lakewood-Amedex Biotherapeutics surged 212% to $5.81 after releasing Nu-3 resistance data."
datetime: "2026-07-22T13:40:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293482150.md)
  - [en](https://longbridge.com/en/news/293482150.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293482150.md)
---

# Lakewood-Amedex Biotherapeutics soars 212% on Nu-3 drug data

Lakewood-Amedex Biotherapeutics(LABT.US) 盘中涨**212.37%**，现报**5.81**美元。

该股从**1.86**美元涨至**5.81**美元，盘中 5 分钟内急涨超**5%**触发异动信号。公司 7 月 22 日发布其二期候选药物 Nu-3 针对感染性糖尿病足溃疡的耐药性数据，连续传代研究显示未诱导耐药性，支持其膜破坏机制在抗菌耐药性领域的开发潜力。

### Related Stocks

- [LABT.US](https://longbridge.com/en/quote/LABT.US.md)

## Related News & Research

- [Lakewood-Amedex Biotherapeutics flags new press release available on Nu-3 resistance data](https://longbridge.com/en/news/293470541.md)
- [Lakewood-Amedex Biotherapeutics makes Investor Deck public, Nu-3 Phase 2a planned with IND open](https://longbridge.com/en/news/292813307.md)
- [08:02 ETLakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers](https://longbridge.com/en/news/287767752.md)
- [Lakewood-Amedex Biotherapeutics Inc. 1Q 2026: Revenue ($886.75K), EPS ($0.2) — 10-Q Summary](https://longbridge.com/en/news/287405274.md)
- [Top Biotech Gainers: ZCMD Surges 190%, LABT Advances On Nu-3 Progress, ARWR Hits The Targets](https://longbridge.com/en/news/293552010.md)